• Miscellaneous urogenital disorders

Procysbi Generic Name & Formulations

General Description

Cysteamine bitartrate 25mg, 75mg; del-rel caps.

Pharmacological Class

Cystine-depleting agent.

How Supplied

Caps 25mg—60; 75mg—250; Granules—60, 120

Procysbi Indications


Nephropathic cystinosis in patients ≥1yr of age.

Procysbi Dosage and Administration

Adults and Children

<1yr: not established. Initiate immediately after diagnosis. Round dose to nearest available strength of caps or packets. Take on an empty stomach. Swallow caps whole with water or fruit juice (except grapefruit). Sprinkle and mix contents of cap (if unable to swallow whole) or intact granules from packet on 4oz of food (eg, applesauce or berry jelly) or 4oz of fruit juice (except grapefruit); also, may administer via feeding tube after mixing with 4oz of applesauce. Cysteamine-naive: initiate at ⅙ to ¼ of the maintenance dose; (1–<6yrs): increase gradually in 10% increments allowing at least 2 weeks between dose adjustments; (≥6yrs): increase gradually over 4–6 weeks. Maintenance: 1.3g/m2/day, in 2 divided doses given every 12hrs; may further increase to achieve therapeutic target WBC cystine level. Max 1.95g/m2/day (if >50kg: max 1000mg every 12hrs). Goal of therapy: to maintain WBC cystine level <1nmol ½ cystine/mg protein (with mixed leukocyte assay). Switching from immediate-release cysteamine: give previous total daily dose of immediate-release formulation. Dose titration, measuring WBC cystine levels: see full labeling.

Procysbi Contraindications


Penicillamine hypersensitivity.

Procysbi Boxed Warnings

Not Applicable

Procysbi Warnings/Precautions


Monitor for development of skin or bone lesions; interrupt dosing if occur; may restart at a lower dose. Permanently discontinue if severe skin rash develops. GI ulceration and bleeding. Consider lowering the dose if severe GI symptoms develop. Fibrosing colonopathy; permanently discontinue and switch to immediate-release cysteamine if confirmed. CNS symptoms (eg, somnolence, encephalopathy, seizures, others); interrupt or adjust dose if severe, persist or progress. Monitor WBCs and alkaline phosphatase levels. Monitor for signs/symptoms of benign intracranial hypertension; permanently discontinue if confirmed. Pregnancy. Nursing mothers: not recommended.

Procysbi Pharmacokinetics

See Literature

Procysbi Interactions


Avoid alcohol. Concomitant drugs that increase gastric pH (eg, PPIs); monitor WBC cystine levels. Separate dosing of carbonate- or bicarbonate-containing products by at least 1hr before or 1hr after. May give concomitant Vit.D, thyroid hormone, or other electrolyte/mineral replacements for Fanconi syndrome.

Procysbi Adverse Reactions

Adverse Reactions

Vomiting, nausea, abdominal pain, breath or skin odor, diarrhea, fatigue, rash, headache, gastroenteritis, electrolyte imbalance; Ehlers-Danlos-like syndrome, leukopenia, elevated alkaline phosphatase, papilledema.

Procysbi Clinical Trials

See Literature

Procysbi Note

Not Applicable

Procysbi Patient Counseling

See Literature